Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Other Current Liabilities

Last Annual Value

3.01M

3-Year CAGR

41%

5-Year CAGR

56%

10-Year CAGR

26%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Other Current Liabilities

SERA · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
3.01M
48.1%-3.3%N/A 
8.32M
18.9%15.5%N/A
8.21M
74.5%31.1%12.2%
5.38M
101.1%128.9%N/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
23.91M
-15.6%15.0%N/A
0.00
N/AN/AN/A
7.72M
24.4%2.9%66.9%
3.36M
115.2%N/AN/A
3.46M
38.9%N/A15.4%
-865.39M
N/AN/AN/A
5.72M
246.9%65.8%67.4%
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245